Articles Related to Biopharmaceutics Classification System
Croscarmellose Sodium Efficiency in the Development of a Generic Capsule Formulation of Piroxicam, Comparable Dissolution Profile to the Innovator Product, Feldene
The objective of this study was to evaluate the encapsulation performance of Croscarmellose sodium, a superdisintegrant in a low-dose, poor-solubility drug formulation and the in-vitro dissolution performance of the Piroxicam capsules. Preparation, characterization and evaluation of the effects of the different concentrations of carmellose sodium and the amount of dried starch on in-vitro dissolution of Piroxicam capsules. Piroxicam was chosen for its very low solubility in biological fluids, which result in poor systemic bioavailability after oral administration. Piroxicam can be categorized as Class II drugs according to the Biopharmaceutics Classification System.
Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
Seventeen alpha hydroxyprogesterone caproate (17-OHPC) is the only FDA-approved drug labeled for prevention of preterm delivery. This drug is also available as a compounded product from licensed compounding pharmacies. This article reviews the FDA approval history and pharmacy compounding quality control data of 17-OHPC, as well as briefly discusses possible future pharmaceutical development strategies for 17-OHPC.